Sign in
Taking people in United StatesNo phase

Joint embolization for long-lasting shoulder, hip or knee pain with osteoarthritis

Tests blood-flow scans and joint embolization in veterans with chronic joint pain.

Key facts

Who runs it
Palo Alto Veterans Institute for Research
Where
Palo Alto, United StatesSee the site
Trial code
Registry title
Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee
Status
Recruiting
People taking part
120 people, planned
Started
15 Jul 2023
Planned end
1 Aug 2026
Type of study
Observational, 2 groups
Treatments tested
  • Shoulder/Hip/Knee Embolization with Embozene Microspheres
Record updated
7 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Veterans who get care in the VA system and have had shoulder, hip or knee pain for at least 1 year. Everyone gets a blood-flow MRI. People with extra blood vessels around the joint can choose a treatment that blocks those vessels (embolization).

Age
25 Years to 80 Years
Sex
All sexes
Disease stage
Long-lasting pain of the shoulder, hip or knee for at least 1 year. Mild to moderate wear of the painful joint seen on earlier X-ray, CT or MRI. A doctor must have ordered an MRI of the painful joint. For the treatment part, the blood-flow MRI must show extra blood vessels around the joint.
Earlier treatment
At least one first treatment for the pain did not work (for example physical therapy, NSAIDs, steroid injection). People who had a joint replacement or metal implant in the painful joint cannot join.
Biomarker or test result
For the treatment part: extra blood vessels around the joint (peri-articular hypervascularity) on perfusion MRI, judged by the study leaders.

Main reasons for not taking part

  • Injury to the joint in the last 12 weeks, or severe joint wear
  • Severe allergy to gadolinium or iodinated contrast dye
  • Severe kidney disease or ongoing dialysis
  • Current pregnancy, or a formal diagnosis of cognitive impairment
  • Cancer with less than one year to live or cancer spread to bone

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Participants must be Veterans who receive care in the VA system
  • Participants must have a history of chronic pain of the shoulder, hip or knee for at least 1 year
  • Participants must have mild to moderate degenerative changes of the painful joint as depicted on prior imaging (X-ray, CT or MRI)
  • Participants must have undergone at least one failed primary treatment for their chronic pain (e.g. physical therapy, NSAIDs, steroid injection)
  • Participants must have an MRI of their painful joint (shoulder, hip or knee) ordered by a clinical provider
  • Participants must have enrolled in the Diagnostic Arm of the study and must have undergone perfusion MR imaging of their painful joint
  • Participants must have evidence of peri-articular hypervascularity on their perfusion MR exams. This will be determined by the study PIs

Who cannot take part

  • Prior upper or lower extremity arterial bypass
  • History of arthroplasty or metallic implant within the painful joint
  • Severe gadolinium contrast allergy
  • Severe renal disease or ongoing dialysis
  • History of malignancy with life expectancy of less than one year, or malignancy with known bone metastasis
  • Formal diagnosis of cognitive impairment
  • Severe iodinated contrast allergy
  • Severe coronary or peripheral arterial disease
  • Uncontrolled type 2 diabetes or diabetic neuropathy
  • History of seizures or other severe complication from conscious sedation
  • Age under 25
  • Acute injury in the last 12 weeks
  • Severe degenerative changes of painful joint (shoulder, hip or knee)
  • Current pregnancy
  • Coagulopathy
  • Ongoing participation in another interventional (therapeutic) trial for chronic joint pain
  • Lack of peri-articular hypervascularity on initial perfusion MRI
  • All exclusion criteria for the Diagnostic Arm

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 80 years old?

Where in United States

  • VA Palo Alto Healthcare SystemPalo Alto, United StatesContact: Eric Bultman, MD/PhDTaking people

About the trial

What the trial wants to find out

In this work the investigators will study the relationship between chronic musculoskeletal pain and abnormal blood flow (neovascularity) around the shoulder, hip and knee. Veterans with as history of chronic shoulder, hip or knee pain and mild/moderate joint degenerative changes will be potential study subjects. Blood flow around joints will be evaluated using perfusion magnetic resonance imaging (MRI). Participants with demonstrably abnormal blood flow around their painful joint will be eligible for enrollment in a pilot study of joint embolization to treat their pain. Participants who choose to not undergo treatment will be re-assessed with MRI after one year to characterize the natural history of joint neovascularity and its relationship to pain.

The 2 groups in the trial

  • Diagnostic

    The investigators will target VA patients with clinically-ordered knee, hip and shoulder MRIs for recruitment (40 for each joint). Patients who elect to participate will undergo perfusion MRI add-on sequence at the end of their clinical MRI. Arterial-phase maximum intensity projection images from the perfusion MR data will be generated, and the presence of abnormal vascularity about each joint will be assessed by the study principal investigators. Participants who have focal or generalized peri-articular hypervascularity will be offered enrollment in the Therapeutic Arm of the study. Those participants who decline enrollment into the Therapeutic Arm, and those without significant peri-articular vascularity on perfusion MRI, will be asked to return for follow-up clinical and imaging visits so that the natural history of pain/imaging parameters in the absence of treatment can be evaluated.

  • Therapeutic

    Of 40 participants enrolled for each joint, the investigators anticipate 20 will choose to enroll in an embolization pilot study. Participants must have peri-articular hypervascularity on perfusion MRI and must have failed at least one first line therapy for their pain to be eligible. Embolization will be performed as an outpatient procedure under conscious sedation. Further description of this procedure is available in the study protocol and literature. Technical success will be defined as selective embolization of at least one abnormal peri-articular artery. After embolization, participants will return for clinical follow-up at 1, 3, 6 and 12 months with perfusion MRI performed at the 3- and 12-month visits. Clinical follow-up at 3, 6 and 12 months will consist only of surveys (WOMAC/WORC). Participants will be instructed to avoid additional treatments for their joint pain when possible, and if a second treatment is initiated to report it to the study investigators.

    Treatment: Shoulder/Hip/Knee Embolization with Embozene Microspheres

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Perfusion MRI-targeted Joint Embolization to Diagnose and Treat Neovascularity Associated With Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee: A Prospective Cohort Study
Plain-language title
Joint embolization for long-lasting shoulder, hip or knee pain with osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05700682, who can take part
Record updated
7 August 2025